Results

Total Results: 1,187 records

Showing results for "weeks".

41. Urinary-Incontinence-Treatment Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/urinary-incontinence-treatment_surveillance.pdf
    October 29, 2012 - Placebo (N=323; 12 weeks Fesoterodine vs. … Placebo (n=352; dose: NA) 12 weeks OTG vs. … PFMT (n= 50; twice/day for 15 minutes each, for 12 weeks) 12 weeks APFMT vs. … PFTM (n=15; twice-weekly sessions of 40 min for 6 weeks); control (n=15; dose: NA) 6 weeks Urinary … , for 4 weeks plus two additional sessions, 3 weeks apart) 12 weeks Paula Method (Circular Muscle

42. Juvenile-Arthritis-Dmards Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_surveillance.pdf
    March 14, 2013 - x 12 weeks Measures of inflammation included CRP and ESR. … x 12 weeks 12 weeks- 64/75 (85%) of tocilizumab group vs 9/37 (24%) placebo [P<0.001]. 52 weeks … Remission was recorded in 25% after 24 weeks, 52% after 48 weeks, 75% after 72 weeks, and 98% after … x 12 weeks 12 weeks- 64/75 (85%) of tocilizumab group vs 9/37 (24%) placebo [P<0.001]. 52 weeks … (13 weeks, 95% CI 6-20) or MTX (6 weeks, 95% CI 2-10) Author, year Trial n Subjects Primary

43. Juvenile-Arthritis-Dmards Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_surveillance.pdf
    March 14, 2013 - x 12 weeks Measures of inflammation included CRP and ESR. … x 12 weeks 12 weeks- 64/75 (85%) of tocilizumab group vs 9/37 (24%) placebo [P<0.001]. 52 weeks … Remission was recorded in 25% after 24 weeks, 52% after 48 weeks, 75% after 72 weeks, and 98% after … x 12 weeks 12 weeks- 64/75 (85%) of tocilizumab group vs 9/37 (24%) placebo [P<0.001]. 52 weeks … (13 weeks, 95% CI 6-20) or MTX (6 weeks, 95% CI 2-10) Author, year Trial n Subjects Primary

44. Lumbar-Fusion-Draft-Report-Appendix-D (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/lumbar-fusion-draft-report-appendix-d.xlsx
    January 01, 2019 - B Hyperglycemia (minor event): 0% vs. 3.3% (1/30) NR NR NR Authors report no COI Moderate 2 weeks 1 … B Any AE: 0% vs. 0% NR NR NR High 1 day 2 days 1 week 2 weeks 1 month 12 months Patient satisfaction … CLBP of confirmed facet origin NR NR >6 weeks required for inclusion NR Authors state no difference … syndrome NR 0% (exclusion criteria) 4.3 years 64 82% 29 NR Hypertension: 15% 12 weeks, 24 weeks A vs … B Repeat injection, % (n/N) 3 weeks 40% (80/195) vs. 37.5% (75/189) Allowed to crossover at 6 weeks.

45. Cannabis-2022-Surv-Rep-3-Tables-F1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-tables-F1-4.xlsx
    January 01, 2022 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

46. Microsoft Word - Comp Eff 10.doc (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-2007_research-2007-1.pdf
    January 01, 2007 - 19 14-16 weeks/3-4 months 8 24-26 weeks/6 months 13 10-11 months 2 48 weeks 3 1 year 7 15 … Study durations ranged from 12 weeks to 3 years, with a mean of 55 weeks (median 26 weeks). … Study durations ranged from 12 weeks to 3.3 years, with a median of 26 weeks. … Study durations ranged from 12 weeks to 3 years, with a median of 16 weeks. … Study durations ranged from 12 weeks to 5 years, with a mean of 49 weeks (median 25 weeks).

47. Cannabis-2022-Surv-Rep-3-Table-F5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-table-F5.xlsx
    January 01, 2022 - , Median) Pain Duration, Months Psychiatric Comorbidity % N Interventions Dose Treatment Duration (Weeks … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … to -50.1 vs. -24.9 to -22.2) LS mean difference: −27.84 (95% CI −29.71 to −25.96), p<0.001 PIX from weeks … B Modified pain disability index, weeks 2 to 24 (95% CI −67.78 to -64.01 vs. −45.23 to −41.46), p<0.001 … B MFHW, weeks 2 to 24: (95% CI 46.24 to 50.46 vs. 5.75 to 1.53), p<0.001 MFHW- mental component summary

48. Cannabis-2022-Update-Surv-Rep-1-App-F-5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F-5.xlsx
    January 01, 2022 - , Median) Pain Duration, Months Psychiatric Comorbidity % N Interventions Dose Treatment Duration (Weeks … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … to -50.1 vs. -24.9 to -22.2) LS mean difference: −27.84 (95% CI −29.71 to −25.96), p<0.001 PIX from weeks … B Modified pain disability index, weeks 2 to 24 (95% CI −67.78 to -64.01 vs. −45.23 to −41.46), p<0.001 … B MFHW, weeks 2 to 24: (95% CI 46.24 to 50.46 vs. 5.75 to 1.53), p<0.001 MFHW- mental component summary

49. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/gerd_executive.pdf
    September 01, 2011 - and healing of esophagitis at 8 weeks. … ; (3) esomeprazole 20 mg versus omeprazole 20 mg in relief of symptoms at 4 weeks. … , and pantoprazole 20 mg better control of heartburn than esomeprazole 20 mg over 24 weeks. … No significant difference in symptom resolution rates was observed at 4 weeks between esomeprazole 20 … , and pantoprazole 40 mg better relief than esomeprazole 40 mg over 24 weeks.

50. Noninvasive Treatments for Low Back Pain: A Summary of the Research for Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/back-pain-treatment_consumer.pdf
    November 01, 2016 - � Acute low back pain lasts for 4 weeks or less. … � Subacute low back pain lasts between 4 weeks and 12 weeks. … � Chronic low back pain lasts for 12 weeks or longer. … Low back pain often improves in 4 weeks or less. … low back pain (lasts between 4 weeks and 12 weeks).

51. Cer-250-Cannabis-2024-Surv-Rep-Update-Tables-E1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-tables-e1-4.xlsx
    January 01, 2024 - , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … CBD 5 mg, increased during weeks 1-4 to a max daily dose of 10 capsules per day (50 mg). … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

52. Treatments for Acute Pain: A Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-protocol-acute-pain-treatments.pdf
    August 08, 2019 - ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to <4 weeks; ≥4 weeks Setting Emergency department (initiation of therapy and following discharge

53. Executive Summary - Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-executive-summary-2023-update.pdf
    January 01, 2023 - In patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks to <6 months): … We included randomized controlled trials and comparative observational studies with a minimum of 4 weeks … 8.25 to 8.67) 6.48 (4 to 8.1)h 5.87 (4.67 to 7.4)i 6.28 (6.12 to 6.44) Study Duration 4 to 15 weeks … 8 to 12 weeks 4 to 47 weeks 4 to 16 weeks 4 weeks Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin … Key Question 2: Harms of cannabinoids for chronic pain compared with placebo in the short term (4 weeks

54. Systematic Review on Treatments for Acute Pain: Surveillance Report 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/main-apps-surv-rept-1-acute-pain.pdf
    May 01, 2022 - ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to less than 4 weeks; 4 weeks or longer? … ; 2 weeks to 4 weeks; ≥4 weeks NOTE: There will not be exclusion criteria for duration, unless duration

55. Evidence Summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-evidence-summary-2022-update_0.pdf
    January 01, 2022 - In patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks to <6 months) … We included randomized controlled trials and comparative observational studies with a minimum of 4 weeks … 8 to 12 weeks 4 to 47 weeks 4 weeks (topical) and 12 weeks (oral) 4 weeks Abbreviations: CBD … Synthetic THC Study Duration, Weeks (Range) 12 to 208 52 26 24 Abbreviations: CBD = cannabidiol … Key Question 2: Harms of cannabinoids for chronic pain compared with placebo in the short term (4 weeks

56. Cannabis-App-F1-F4-Tables-Surveillance-Report-2 0 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f1-f4-tables-surveillance-report-2_0_0.xlsx
    May 29, 2025 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

57. Cannabis-2023-Surv-Rep-1-App-F (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-1-app-F.xlsx
    January 01, 2023 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

58. Cannabis-2022-Surv-Rep-4-Tables-F1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-tables-F1-4.xlsx
    January 01, 2022 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

59. Cannabis-2023-Surv-Rep-4-Tables-E-1-E-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-tables-E-1-E-4.xlsx
    January 01, 2023 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

60. Cer-238-Cervical-Ripening-Appendix-E-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-238-cervical-ripening-appendix-e-1.xlsx
    January 01, 2009 - 42 weeks with inpatient cervical ripening if necessary. … -If they passed 42 weeks of gestation, then patients were admitted for induction. … and 4 days and 41 weeks. … -Subjects were instructed to return at 40 and 41 weeks for routine reassessments. … Fetal heart rate monitoring was done only if clinically indicated at 40 weeks and routinely at 41 weeks